Nucleai from LinkedIn
Nucleai, an Israeli medtech startup that uses artificial intelligence (AI) powered spatial biology to transform drug development and clinical treatment decisions for precision cancer treatments, raised $14 million in new investment led by M Ventures. The raise brings Nucleai’s total funding to date to $60 million.
Spatial Biology is the study of tissues within their own 2D or 3D context. Think of how a GPS system captures location coordinates within an area and tracks your location at a given time – the same principle can be used on a cellular and molecular level for the treatment of disease.
Both Israel Startup Nation firms and Israeli scientists are making breakthroughs in the treatment of cancer. For example, researchers from Tel Aviv University recently found that a combination of drugs already available on the market can hinder bone metastasis and improve survival in cases of breast cancer.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Established in 2018, Nucleai is an AI-powered spatial biology company who declares its mission to be to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making.
By moving beyond traditional pathology’s analog analysis, Nucleai leverages AI to create dynamic, digital maps from biopsy samples, uncovering the complex interactions at play within tissue. This innovation marks a shift in disease diagnosis and treatment, offering an in-depth contextual view that underpins the development of novel therapeutics.
Avi Veidman, CEO and Co-Founder of Nucleai, said, “M Ventures’ investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics. Our vision is that every next-generation therapeutic is accompanied with an AI-enabled companion diagnostic, ensuring that each patient’s treatment pathway is informed and efficacious. This funding positions us to scale spatial AI, not just to intercept but anticipate the complex behavior of diseases.”
